Indivior Plc - Company Profile
Powered by 
All the data and insights you need on Indivior Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Indivior Plc Strategy Report
- Understand Indivior Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Indivior Plc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| CA2964103C | Grant | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | A61K31/4196; A61K31/422; A61P25/12; A61P25/18; A61P25/30; A61P43/00; C07B2200/13; C07D209/54; C07D221/20; C07D401/14; C07D403/12; C07D403/14; C07D405/14; C07D409/14; C07D413/14; C07D417/14; C07D471/04; C07D493/08; C07F7/1804 | August 30, 2022 |
| CA2992820C | Grant | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | A61K31/407; A61K31/5383; A61P25/18; A61P25/30; A61P25/32; A61P25/36; C07D209/52; C07D487/04; C07D498/04 | August 16, 2022 |
| EP3863712A4 | Search Report | BUPRENORPHIN ZUR BEHANDLUNG VON ATEMDEPRESSION | A61K31/485; A61K47/14; A61K47/26; A61K47/32; A61K47/34; A61K9/0019; A61K9/0024; A61P11/00; A61P11/06; A61P11/08; C07D489/02 | July 20, 2022 |
| NZ731309A | Application | Buprenorphine dosing regimens | A61K31/485; A61K47/22; A61K47/34; A61K9/0019; A61P25/04; A61P25/36 | February 25, 2022 |
| US20220031692A1 | Application | BUPRENORPHINE DOSING REGIMENS | A61K31/485; A61K47/22; A61K47/34; A61K9/0019 | February 03, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer